Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

InMed Pharmaceuticals (INM) Equity Ratio (2020 - 2026)

InMed Pharmaceuticals has reported Equity Ratio over the past 5 years, most recently at 0.86 for Q4 2025.

  • For Q4 2025, Equity Ratio rose 17.82% year-over-year to 0.86; the TTM value through Dec 2025 reached 0.86, up 17.82%, while the annual FY2025 figure was 0.86, 10.74% up from the prior year.
  • Equity Ratio for Q4 2025 was 0.86 at InMed Pharmaceuticals, down from 0.87 in the prior quarter.
  • Over five years, Equity Ratio peaked at 0.88 in Q3 2021 and troughed at 0.88 in Q3 2023.
  • A 5-year average of 0.71 and a median of 0.8 in 2024 define the central range for Equity Ratio.
  • Biggest five-year swings in Equity Ratio: plummeted 216.24% in 2023 and later skyrocketed 191.44% in 2024.
  • Year by year, Equity Ratio stood at 0.73 in 2021, then grew by 15.92% to 0.85 in 2022, then fell by 1.18% to 0.84 in 2023, then fell by 13.15% to 0.73 in 2024, then rose by 17.82% to 0.86 in 2025.
  • Business Quant data shows Equity Ratio for INM at 0.86 in Q4 2025, 0.87 in Q3 2025, and 0.86 in Q2 2025.